Product
Octreotide
Aliases
high dose long-acting octreotide, octreotide acetate, Octreotide Acetate, Octreotide LAR (2 other aliases)
Name
Octreotide Acetate
INN Name
octreotide acetate
FDA Approved
Yes
24 clinical trials
9 organizations
39 indications
3 documents
Indication
Healthy Control ParticipantsIndication
Neuroendocrine TumorsIndication
TachycardiaIndication
Liver ResectionIndication
Chronic Orthostatic IntoleranceIndication
Pancreatic Neuroendocrine Tumor Grade 2Indication
Hepatocellular CarcinomaIndication
Hepatic MetastasisIndication
Neuroendocrine CarcinomaIndication
Islet Cell CarcinomaIndication
Hepatorenal syndromeIndication
CirrhosisIndication
Kidney FailureIndication
AcuteIndication
Polycystic Kidney DiseaseIndication
Esophageal VaricesIndication
Upper Gastrointestinal BleedingIndication
AngiodysplasiaIndication
Vascular MalformationsIndication
Gastrointestinal HemorrhageIndication
AnaemiaIndication
Thymoma and Thymic CarcinomaIndication
Colorectal CancerIndication
DiarrheaIndication
Lymphatic DiseasesIndication
ChylothoraxIndication
Colorectal Neuroendocrine Tumor G1Indication
Gastric Neuroendocrine Tumor G1Indication
Neuroendocrine TumorIndication
Liver TransplantIndication
Hemorrhagic ShockIndication
Variceal HemorrhageIndication
Esophageal NeoplasmsIndication
Stomach NeoplasmsIndication
Unintentional Weight LossIndication
MalnutritionIndication
Pancreatic CancerIndication
Duodenal NeoplasmsClinical trial
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NETStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETStatus: Active (not recruiting), Estimated PCD: 2023-07-20
Clinical trial
Bioequivalence Study of Octreotide Acetate Microsphere Injection in HumanStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, , Well Differentiated， Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine TumoursStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine TumorsStatus: Not yet recruiting, Estimated PCD: 2027-11-26
Clinical trial
Treatment of Orthostatic IntoleranceStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
GI-072: Randomized Controlled Trial of the Use of Octreotide to Enhance Liver Recovery After Major HepatectomyStatus: Terminated, Estimated PCD: 2020-02-12
Clinical trial
Real-world Effectiveness of Adjuvant Octreotide Therapy in High Recurrence Risk Patients With Pancreatic Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2020-04-01
Clinical trial
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.Status: Recruiting, Estimated PCD: 2025-08-14
Clinical trial
Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)Status: Completed, Estimated PCD: 2009-07-01
Clinical trial
Angiotensin 2 as a Novel Treatment for Hepatorenal SyndromeStatus: Withdrawn, Estimated PCD: 2023-06-30
Clinical trial
A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2023-04-10
Clinical trial
Evaluating Baseline Predictors Including Total Kidney Volume, of Chronic GFR Decline and Other Clinical Outcomes in Outpatients With ADPKD and Stage IV CKD on Chronic Treatment With Octreotide LAR: a Retrospective, Observational StudyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anemia Due to AngiodysplasiasStatus: Completed, Estimated PCD: 2022-07-01
Clinical trial
Phase II Study of Octreotide Treatment of Advanced, Recurrent ThymomaStatus: , Estimated PCD: 2003-09-01
Clinical trial
Randomized Trial of High-Dose Versus Conventional Dose Octreotide Acetate Versus Loperamide in the Treatment of Chemotherpay-Related Diarrhea in Patients With Colorectal CancerStatus: , Estimated PCD: 2000-05-01
Clinical trial
Octreotide Improves Human Lymphatic Fluid Transport a Translational TrialStatus: Completed, Estimated PCD: 2021-03-26
Clinical trial
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid PatientsStatus: Active (not recruiting), Estimated PCD: 2015-01-01
Clinical trial
A Double-blind Randomised Placebo-controlled Feasibility Study to Assess the Impact of Octreotide Infusion During Liver Transplantation on Post-operative Renal Failure.Status: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic ShockStatus: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal SurgeryStatus: Completed, Estimated PCD: 2018-03-01
Clinical trial
Food Intake and Gut Hormone Release in Patients in Cancer Remission Who Have Undergone Upper Gastrointestinal SurgeryStatus: Completed, Estimated PCD: 2017-12-01
Organization
bryant ranch prepackOrganization
Hikma Pharmaceuticals USA Inc.Document
DailyMed Label: Octreotide
Organization
Glenmark Pharmaceuticals Inc., USAOrganization
Sagent PharmaceuticalsOrganization
Gland Pharma LimitedOrganization
Mylan Institutional LLCOrganization
Fresenius Kabi USA, LLC
Organization
Novartis Pharmaceuticals Corporation